MilliporeSigma Signs MoU with Synplogen to Accelerate Development and Manufacturing of Viral Vector-based Gene Therapy Applications

MilliporeSigma has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation.

13 Dec 2022 | Burlington, Massachusetts, United States of America
  • Company’s Millipore® CTDMO Services (Contract Testing, Development and Manufacturing Organization) to streamline viral vector development and production in Japan 
  • Collaboration includes VirusExpress® Platform to accelerate development and clinical research 
  • MilliporeSigma to provide hands-on training to Synplogen scientists at M Lab™ Collaboration Center in Japan 

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to provide streamlined development, manufacturing and testing for viral vector gene therapies for Japan.

“With nearly 30 years’ experience in cell and gene therapy, we look forward to collaborating with Synplogen to further the development and manufacturing of viral vectors in Japan,” said Isao Hatano, Head of Process Solutions, Japan, Life Science business sector of Merck KGaA, Darmstadt, Germany. “Our work together will focus on developing the targeted template and manufacturing for viral vectors in order to bring these life-changing therapies to more patients.”

The collaboration also includes licensing MilliporeSigma’s VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform. It will enable Synplogen to increase the speed to clinical manufacturing, while reducing process development time and costs. The approach will leverage the company’s Millipore® CTDMO Services facility in Carlsbad, California, USA, which opened in 2021 to support large-scale commercial and industrial manufacturing of viral and gene therapy products. 

“Synplogen has been providing customers with the technologies and services including DNA synthesis, cell, process and test method development necessary for gene therapy products, a market that has grown dramatically in recent years. Our collaboration with MilliporeSigma will enable us to provide a full range of services from Chemistry, Manufacturing and Control development to GMP manufacturing and potentially expand the business globally, by licensing our proprietary technologies to overseas companies,” said Kazuhiko Yamamoto, Representative Director and CEO of Synplogen Co., Ltd.

As part of the MoU, MilliporeSigma will offer technical support, training and process development and optimization at its M Lab™ Collaboration Center in Tokyo. The company operates M Lab™ Collaboration Centers in nine countries worldwide, where its scientists and engineers provide customers with opportunities for collaboration, technical guidance, and education in a fully simulated bioprocessing manufacturing lab environment. 


For more information, contact Rachel Bloom-Baglin

About Synplogen

Synplogen Co., Ltd. is a synthetic biology startup company founded in 2017 and originated from Kobe University. Utilizing its proprietary DNA synthesis technologies "OGAB method" and "Combi-OGAB method", the company is capable of synthesizing ultra-long and complex DNA and constructing DNA libraries with various combinations. We also provide one-stop solutions for the design, development, and analysis of high-quality, cost-effective viral vectors for gene therapy at our Kobe R&D Center, as a biofoundry specializing in gene therapy. URL:

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated sales of € 19.7 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription to this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service. 

Related News

  1. Press Releases

    MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity ...

    > >>Curiosity Cube mobile science lab plans to reach 45,000 students in 14 countries>> >>Lessons educate students on sustainability topics, such as renewable energy and recycled materials>> >>Reinforces company ...